Neurology

Transcranial direct current stimulation shows promise in addressing fatigue in patients with multiple sclerosis.

Study results show a genetic risk variant on astrocytes enhances the accessibility of the central nervous system (CNS) to peripheral immune cells, escalating the risk of autoimmune inflammation and multiple sclerosis.

From clinical trials evaluating treatments to studies unearthing new discoveries about the disease's mechanism, these were some of the top newsworthy moments in multiple sclerosis research in 2018.

Top news of the day across the health care landscape.

Experts argue whether a decline in cognitive function should lead to a change in disease-modifying therapy for multiple sclerosis.

Health care providers managing patients with MS should remain cognizant of the link between unhealthy lifestyle behaviors and depression risks.

FDA finds rare but serious risks of stroke and blood vessel wall tears associated with the multiple sclerosis drug alemtuzumab (Lemtrada).

It’s our job to spend as much time as it takes to help patients feel comfortable with the medications they are taking.

The FDA advises health care providers to counsel patients receiving alemtuzumab on symptoms related to stroke and arterial dissection.

FDA officials are warning that stopping treatment with the multiple sclerosis (MS) drug fingolimod (Gilenya) can cause severe worsening.

FDA officials are warning that stopping treatment with the multiple sclerosis (MS) drug fingolimod (Gilenya) can cause severe worsening.

Stopping treatment with fingolimod (Gilenya) can cause the disease to become much worse than before the medicine was started or while it was being taken, FDA officials warned.

New study finds that ocrelizumab (Ocrevus) has the capability to reduce risk of upper extremity disability progression in patients with primary progressive multiple sclerosis (PPMS).

Top news of the day from across the health care landscape.

Study explores the effect of microglia dysregulation on progression of neurodegeneration in disorders such as Alzheimer disease and amyotrophic lateral sclerosis.

Certain environmental conditions, such as salinity and temperature, may incite structural changes in myelin sheaths.

New data from the investigational multiple sclerosis (MS) drug evobrutinib showed that the therapy reduced lesions and decreased annual relapse rates in patients with relapsing MS.

A post hoc analysis of clinical trial data showed oral ozanimod improved cognitive processing speed and reduced annualized relapse rates and MRI lesions in multiple sclerosis.

Phase 2 data for evobrutinib shows reduction in lesions and relapse rates in patients with multiple sclerosis.

Survey participants reported need for better education on how brain atrophy affects multiple sclerosis progression and cognitive loss.

Fingolimod (Gilenya) found to significantly reduce the annualized relapse rate compared with glatiramer acetate among patients with relapsing-remitting multiple sclerosis.

New 5-year data from phase 3 studies show that patients treated earlier with ocrelizumab (Ocrevus) had better outcomes on multiple measures of multiple sclerosis disease activity.

Siponimod is an oral, once-daily medication for the treatment of multiple sclerosis in adults.

Efavirenz exposure (EVF) in utero is being linked to higher risk of neurologic abnormalities in infants and children.

Brain inflammation caused by critical illness and infection may lead to the observed reduction in brain volume.